(CercleFinance.com) – GSK announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation to its investigational vaccine against Neisseria gonorrhoeae (NgG).
The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by evaluating the efficacy of the NgG vaccine in healthy adults, ages 18-50, considered at risk for gonorrhea. .
The Fast Track designation is intended to facilitate the development and expedite the review of potentially important new drugs and vaccines to treat or prevent serious conditions with unmet medical needs.
Gonorrhea is the second most common bacterial sexually transmitted infection (STI) in the world, with an estimated 82 million new cases worldwide each year.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
This is a Smartvoice article: see legal notice